Silence Therapeutics is a biotechnology company developing siRNA (short interfering RNA) therapeutics that silence disease-associated genes using its proprietary mRNAi GOLD platform, which uses GalNAc conjugation to deliver molecules to the liver and enable gene silencing through RNA interference. The company's pipeline spans rare diseases, including divesiran for polycythemia vera and SLN548 for complement-mediated renal diseases, and cardiometabolic diseases, including zerlasiran for cardiovascular disease via lipoprotein(a) lowering, candidates targeting ANGPTL3, GPR146, and INHBE for various metabolic conditions, and an obesity candidate addressing limitations of current therapies. Silence currently has no approved products and generates minimal revenue from milestone payments and potential royalties under collaboration agreements; the company is seeking third-party partners for Phase 3 development and commercialization to reduce capital requirements and accelerate timelines to market.